23 Total results for product and free and sample content found
HHS’ “First 100 Days” take on the drug pricing “Blueprint” is a novel use of a tried-and-true milestone for presidential action. But it is probably more enlightening to look at what has happened in the 1,000 days since drug pricing became the overwhelming focus of political attention.
Letter initiated by six CEOs drew 'absolutely overwhelming' response as 163 leaders of primarily small biotech and venture capital firms signed on; tech firms join court fight.
Followers of rogue FDA twitter site AltFDA answered a call to back up inspection citations data the Obama administration made public in case the Trump administration erases it from the FDA website.
Big pharma has been muted in its response to President Trump's executive order imposing severe travel restrictions on nationals from seven Muslim-majority countries for 90 days. Small biotech, however, has no reservations about speaking out against the so-called 'immigration ban'.
The Trump presidency and the threat of protectionism, new generic opportunities beyond the US market, and the need for new quality benchmarks were some of the key issues discussed at the recent annual day celebrations of the Indian Drug Manufacturers’ Association.
Incoming president not holding over any FDA political appointees from the Obama administration, but what exactly his stamp on the agency will be remains unclear.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: